ELSEVIER

International Journal of Antimicrobial Agents 7 (1996) 295–297

INTERNATIONAL JOURNAL OF
Antimicrobial
Agents

Author index

Volume 7 (1996)

Ako-Nai, A.K., see Lamikanra, A. **7**, 59
Amichai, B., see H. Grunwald, M. **7**, 187
Amyes, S.G.B., see Shanahan, P.M.A. **7**, 153
Ansolis, L.E., see Sidorenko, S.V. **7**, 109

Bacon, T.H., Famciclovir, from the bench to the patient a comprehensive review of preclinical data **7**, 119
Baiocchi, P., A. Capone, P. Carfagna, C. Santini, M. Venditti, Changes in susceptibilities to teicoplanin, vancomycin and other antibiotics among *Staphylococcus aureus* isolates in a tertiary-care University hospital **7**, 93
Balfour Jr., H., Prevention of cytomegalovirus disease **7**, 283
Barry, A.L., see Brown, S. **7**, 53
Bartelink, A.K.M., see Bouter, K.P. **7**, 143
Bauer, M., see Nichterlein, T. **7**, 75
Borleffs, J.C.C., see van der Feltz, M. **7**, 135
Borobio, M.V., A. Pascual, M.C. Dominguez, A.I. Suarez, E. Ramirez, M.C. Conejo, J.A. Pallars, R. Moreno, E.J. Perea, Evolution of the antimicrobial susceptibility of *B. fragilis* group at the university hospital of Seville (Spain) between 1977 and 1995 **7**, 1
Boucher, C.A.B., Individualisation of HIV therapy based on HIV RNA load: the virologist's perspective **7**, 211
Bouter, K.P., F.L.J. Visseren, R.M.M. van Loenhout, A.K.M. Bartelink, D.W. Erkelens, R.J.A. Diepersloot, Treatment of diabetic foot infection: an open randomised comparison of imipenem/cilastatin and piperacillin/clindamycin combination therapy **7**, 143
Brown, S., A.L. Barry, P. Burton, Susceptibility surveillance of U.S. respiratory pathogenisolates to newer macrolide and azalide antibiotics **7**, 53
Bruce, A., see Preston, C. **7**, 251
Bruzzese, T., see Hamilton-Miller, J.M.T. **7**, 247
Burton, P., see Brown, S. **7**, 53

Capone, A., see Baiocchi, P. **7**, 93
Carfagna, P., see Baiocchi, P. **7**, 93
Carlisle, P.S., see Lazarus, H.M. **7**, 85
Catalano, M., see Centrón García, D. **7**, 203
Centrón García, D., M. Catalano, S. Piñeiro, M. Woloj, S. Kaufman, D. O. Sordelli, The emergence of resistance to amikacin in *Serratia marcescens* isolates from patients with nosocomial infection **7**, 203
Chakraborty, T., see Nichterlein, T. **7**, 75
Chang, S.-C., see Chen, Y.-C. **7**, 69
Chang, S.-C., see Chen, Y.-C. **7**, 217
Chen, Y.-C., C.-C. Hung, S.-F. Lin, S.-C. Chang, W.-C. Hsieh, Comparison of flomoxef with latamoxef in the treatment of sepsis and/or Gram-negative bacteremia in adult patients **7**, 69
Chen, Y.-C., S.-C. Chang, W.-C. Hsieh, K.-T. Luh, In vitro antifungal susceptibilities of *Candida* species isolated from the blood **7**, 217
Cimbro, M., see Ferrara, A. **7**, 181
Ciobanu, N., see Lazarus, H.M. **7**, 85
Conejo, M.C., see Borobio, M.V. **7**, 1
Cooper, B.W., see Lazarus, H.M. **7**, 85
Costerton, J.W., see Preston, C. **7**, 251
Creger, R.J., see Lazarus, H.M. **7**, 85

Dacquet, V., Treatment of bone and joint infection with teicoplanin: aretrospective analysis of 50 cases **7**, 49
Darouiche, R.O., see Spindel, S.J. **7**, 149
De Clercq, E., Perspectives for the chemotherapy of respiratory syncytial virus (RSV) infections **7**, 193
de Graaf, L., see van der Feltz, M. **7**, 135
de Haas, C.J.C., see van der Feltz, M. **7**, 135
Denning, D.W., see Law, D. **7**, 241
de Souza, W., see Vivas, Julio A. U **7**, 235
Diepersloot, R.J.A., see Bouter, K.P. **7**, 143
Dominguez, M.C., see Borobio, M.V. **7**, 1
Domann, E., see Nichterlein, T. **7**, 75
Donta, I., see Giamarellou, H. **7**, 23
Dos Santos, C., see Ferrara, A. **7**, 181

Erkelens, D.W., see Bouter, K.P. **7**, 143

Ferrara, A., C. Dos Santos, M. Cimbro, G. Gialdroni Grassi, Comparative antimicrobial activity and post-antibiotic effect of azithromycin, clarithromycin and roxithromycin against some respiratory pathogens **7**, 181
Fox, R.M., see Lazarus, H.M. **7**, 85

Gentile, G., see Volpi, A. **7**, 287
Gialdroni Grassi, G., see Ferrara, A. **7**, 181
Giamarellou, H., P. Tsapogas, A. Pefanis, I. Donta, G. Perdikaris, P. Karayiannakos, Ciprofloxacin and imipenem alone or in combination inexperimental aortic valve endocarditis due to a ciprofloxacinborderline susceptible strain of *Pseudomonasaeruginosa* **7**, 23
Goll, A., see Moyle, G. **7**, 41
Gould, I.M., see Shanahan, P.M.A. **7**, 153
Grausova, S., see Ilavska, I. **7**, 101
Grunwald, M.H., B. Amichai, Dapsone — the treatment of infectious and inflammatory diseases in dermatology **7**, 187

Gucalp, R., see Lazarus, H.M. **7**, 85
Güngör, G., see Tahaoğlu, K. **7**, 261
Gwanzura, L., see Mason, P.R. **7**, 29

Hamilton-Miller, J.M.T., S. Shah, A microbiological assessment of silver fusidate, a novel topical antimicrobial agent **7**, 97
Hamilton-Miller, J.M.T., T. Bruzzese, A. Nonis, S. Shah, Comparative anti-gonococcal activity of S-565, a new rifamycin **7**, 247
Harris, R., see Moyle, G. **7**, 41
Hatipoğlu, T., see Tahaoğlu, K. **7**, 261
Hlawatsch, A., see Nichterlein, T. **7**, 75
Hof, H., see Nichterlein, T. **7**, 75
Hood, J., see Shanahan, P.M.A. **7**, 153
Hsieh, W.-C., see Chen, Y.-C. **7**, 69
Hsieh, W.-C., see Chen, Y.-C. **7**, 217
Hung, C.-C., see Chen, Y.-C. **7**, 69

Ilavska, I., P. Pichna, K. Stopkova, S. Grausova, I. Krupova, E. Oravcova, P. Koren, J. Lacka, M. Studena, S. Spanik, A. Kunova, J. Trupl, V. Krcmery Jr., Polymicrobial bacteremia in cancer patients: analysis of risk factors, etiology and outcome in 214 episodes **7**, 101

Jacobs, M.R., see Lazarus, H.M. **7**, 85
Joseph, L.A., see Law, D. **7**, 241

Kambal, A.M., Antimicrobial susceptibility and serogroups of Salmonella isolates from Riyadh, Saudi Arabia **7**, 265
Karayiannakos, P., see Giamarellou, H. **7**, 23
Katzenstein, D.A., see Mason, P.R. **7**, 29
Kaufman, S., see Centrón García, D. **7**, 203
Keaney, M.G.L., see Law, D. **7**, 241
Khoury, A., see Preston, C. **7**, 251
Koren, P., see Ilavska, I. **7**, 101
Krcmery Jr., V., see Ilavska, I. **7**, 101
Kretschmar, M., see Nichterlein, T. **7**, 75
Krieger, J., see Riley, D. **7**, 257
Krotova, L.A., see Sidorenko, S.V. **7**, 109
Krupova, I., see Ilavska, I. **7**, 101
Kuck, N.A., In vitro activity of piperacillin/tazobactam against isolates from patients enrolled in clinical trials **7**, 15
Kunova, A., see Ilavska, I. **7**, 101
Kızkın, O., see Tahaoğlu, K. **7**, 261

Lacka, J., see Ilavska, I. **7**, 101
Lamikanra, A., A.K. Ako-Nai, D.A. Ogunniyi, Transferable antibiotic resistance in *Escherichia coli* isolated from healthy Nigerian school children **7**, 59
Latif, A.S., see Mason, P.R. **7**, 29
Law, D., C.B. Moore, L.A. Joseph, M.G.L. Keaney, D.W. Denning, High incidence of antifungal drug resistance in Candida tropicalis **7**, 241
Lazarus, H.M., R.J. Creger, R. Gucalp, R.M. Fox, N. Ciobanu, P.S. Carlisle, B.W. Cooper, M.R. Jacobs, Cefoperazone/sulbactam versus cefoperazone plus mezlocillin: empiric therapy for febrile, neutropenic bone marrow transplant patients **7**, 85
Lin, S.-F., see Chen, Y.-C. **7**, 69
Luh, K.-T., see Chen, Y.-C. **7**, 217

Mason, P.R., L. Gwanzura, A.S. Latif, S. Ray, J. van de Wijgert, D.A. Katzenstein, Antimicrobial susceptibility patterns amongst group B streptocci from women in Harare, Zimbabwe **7**, 29
Miles, R.S., see Shanahan, P.M.A. **7**, 153
Milpied, N., Prophylaxis of cytomegalovirus infection in bone marrow transplant patients **7**, 277
Mohapatra, S., see Ravaoarinora, M. **7**, 65
Moore, C.B., see Law, D. **7**, 241
Moyle, G., A. Goll, S. Snape, R. Harris, C. Wilkes, M. Warburg, M. Salgo, Safety and tolerability of zalcitabine (ddC) in patients with AIDS or advanced AIDS-related complex in the European Expanded Access Programme **7**, 41
Murata, M., see Ohnishi, K. **7**, 231

Nichterlein, T., E. Domann, M. Kretschmar, M. Bauer, A. Hlawatsch, H. Hof, T. Chakraborty, Subinhibitory concentrations of β-lactams and other cell-wall antibiotics inhibit listeriolysin production by *Listeria monocytogenes* **7**, 75
Nicolau, D., P. Tessier, C. Nightingale, R. Quintiliani, Influence of ticlopidine on the development of experimental *Staphylococcus aureus* endocarditis **7**, 271
Nightingale, C., see Nicolau, D. **7**, 271
Nonis, A., see Hamilton-Miller, J.M.T. **7**, 247

Ogunniyi, D.A., see Lamikanra, A. **7**, 59
Ohnishi, K., M. Murata, Treatment of symptomatic amebic colitis in human immunodeficiency virus-infected persons **7**, 231
Old, D., see Shanahan, P.M.A. **7**, 153
Omri, A., M. Ravaoarinoro, Preparation, properties and the effects of amikacin, netilmicin and tobramycin in free and liposomal formulations in Gram-negative and Gram-positive bacteria **7**, 9
Omri, A., see Ravaoarinora, M. **7**, 65
Oravcova, E., see Ilavska, I. **7**, 101
Oriol, F., see Ravaoarinora, M. **7**, 65

Pallars, R. Moreno, J.A., see Borobio, M.V. **7**, 1
Partal, M., see Tahaoğlu, K. **7**, 261
Pascual, A., see Borobio, M.V. **7**, 1
Pechkovsky, D.V., M.P. Potapnev, O.M. Zalutskaya, Different patterns of cytokine regulation of phagocytosis and bacterial killing by human neutrophils **7**, 33
Pefanis, A., see Giamarellou, H. **7**, 23
Perdikaris, G., see Giamarellou, H. **7**, 23
Perea, E.J., see Borobio, M.V. **7**, 1
Pichna, P., see Ilavska, I. **7**, 101
Piñeiro, S., see Centrón García, D. **7**, 203
Potapnev, M.P., see Pechkovsky, D.V. **7**, 33
Preston, C., A. Khoury, G. Reid, A. Bruce, J.W. Costerton, *Pseudomonas aeruginosa* biofilms are more susceptible to ciprofloxacin than to tobramycin **7**, 251

Quintiliani, R., see Nicolau, D. **7**, 271

Ramirez, E., see Borobio, M.V. **7**, 1
Ravaoarinora, M., S. Mohapatra, J. Shore, S. Rawal, A. Omri, J. Yaghi, F. Oriol, Serotyping clinical isolates of *Pseudomonasaeruginosa* in relation to infection site antibiotic susceptibility and beta-lactamase production **7**, 65
Ravaoarinoro, M., see Omri, A. **7**, 9
Rawal, S., see Ravaoarinora, M. **7**, 65
Ray, S., see Mason, P.R. **7**, 29
Reid, G., see Preston, C. **7**, 251
Rezvan, S.P., see Sidorenko, S.V. **7**, 109
Riley, D., J. Krieger, Kinetics of killing or growth of *Trichomonas vaginalis* in the presence of aminoglycosides, neomycin and geneticin (G418) **7**, 257

Saeed, Z.A., see Spindel, S.J. **7**, 149
Salgo, M., see Moyle, G. **7**, 41
Santini, C., see Baiocchi, P. **7**, 93
Shah, S., see Hamilton-Miller, J.M.T. **7**, 97, 247
Shanahan, P.M.A., C.J. Thomson, R.S. Miles, D. Old, J. Hood, I.M. Gould, S.G.B. Amyes, Antibiotic resistance in nosocomial isolates in Scotland **7**, 153
Shore, J., see Ravaoarinora, M. **7**, 65
Sidorenko, S.V., S.P. Rezvan, A.S. Tikchonova, L.A. Krotova, L.E. Ansolis, E.A. Tzvigun, In vitro activity of ampicillin, cefoperazone, their combinations with sulbactam and other antimicrobials: survey of Russian isolates **7**, 109
Snape, S., see Moyle, G. **7**, 41
Sordelli, D.O., see Centrón García, D. **7**, 203
Spanik, S., see Ilavska, I. **7**, 101
Spindel, S.J., R.O. Darouiche, Z.A. Saeed, Hepatosplenic candidiasis in non-neutropenic patients: a case report and literature survey **7**, 149
Stopkova, K., see Ilavska, I. **7**, 101
Studena, M., see Ilavska, I. **7**, 101
Suarez, A.I., see Borobio, M.V. **7**, 1

Tahaoğlu, K., O. Kızkın, T. Hatipoğlu, G. Güngör, M. Partal, Alarming drug-resistance rates for tuberculosis in Süreyyapaşa Hospital, Turkey **7**, 261
Tessier, P., see Nicolau, D. **7**, 271
Thomson, C.J., see Shanahan, P.M.A. **7**, 153
Tikchonova, A.S., see Sidorenko, S.V. **7**, 109
Trupl, J., see Ilavska, I. **7**, 101
Tsapogas, P., see Giamarellou, H. **7**, 23
Tzvigun, E.A., see Sidorenko, S.V. **7**, 109

van der Feltz, M., C.J.C. de Haas, L. de Graaf, M.R. Visser, J. Verhoef, J.C.C. Borleffs, Two rapid complementary methods to detect progressive zidovudine resistance mutations in mononuclear cells of HIV-infected patients **7**, 135
van de Wijgert, J., see Mason, P.R. **7**, 29
van Loenhout, R.M.M., see Bouter, K.P. **7**, 143
Venditti, M., see Baiocchi, P. **7**, 93
Verhoef, J., see van der Feltz, M. **7**, 135
Visseren, F.L.J., see Bouter, K.P. **7**, 143
Visser, M.R., see van der Feltz, M. **7**, 135
Vivas, Julio A. Urbina, W. de Souza, W. de Souza, Ultrastructural alterations in *Trypanosoma* (*Schizotrypanum*) *cruzi* induced by $\Delta^{24(25)}$ sterol methyl transferase inhibitors and their combinations with ketoconazole **7**, 235
Volpi, A., G. Gentile, Future directions on prophylaxis and therapy of cytomegalovirus diseases **7**, 287

Warburg, M., see Moyle, G. **7**, 41
Wilkes, C., see Moyle, G. **7**, 41
Woloj, M., see Centrón García, D. **7**, 203

Yaghi, J., see Ravaoarinora, M. **7**, 65

Zalutskaya, O.M., see Pechkovsky, D.V. **7**, 33